Brooke Montes
Family · San Angelo, TXNPI 1215602412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Amgen at 24.8% of the total. Reporting peaked in 2022 at $1,816 and has fallen 81.5% since, to $336 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$916
- AbbVie$499
- Johnson & Johnson$431
- Mallinckrodt Hospital Products Inc.$372
- Lilly USA, LLC$281
- AstraZeneca$191
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,63898%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 38 | $916 |
| AbbVie | 23 | $499 |
| Johnson & Johnson(2 entities) | 23 | $431 |
| Mallinckrodt Hospital Products Inc. | 14 | $372 |
| Lilly USA, LLC | 14 | $281 |
| AstraZeneca | 11 | $191 |
| Novo Nordisk | 5 | $184 |
| UCB, Inc. | 5 | $149 |
| Sanofi | 1 | $91 |
| Radius Health, Inc. | 3 | $64 |
| Gilead | 3 | $56 |
| Genentech USA, Inc. | 3 | $56 |
| Exact Sciences | 3 | $54 |
| Novartis | 1 | $42 |
| Sobi, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $30 |
| Cumberland Pharmaceuticals, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| GSK | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$123
How this compares
$3,698 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $20,557 |
| JardianceEmpagliflozin | 14 | $13,080 |
| MounjaroTirzepatide | 11 | $10,082 |
| TradjentaLinagliptin | 13 | $9,195 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,931 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,273 |
| Gabapentin | 24 | $789 |
| Amitriptyline Hcl | 14 | $474 |
| Levothyroxine Sodium | 68 | $455 |
| Duloxetine Hcl | 26 | $428 |
| Atorvastatin Calcium | 84 | $366 |
| Glipizide ErGlipizide | 11 | $336 |
| Lisinopril | 56 | $245 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $244 |
| Montelukast Sodium | 25 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $30 | $22,27427 claims |
| Novo NordiskOzempic | $184 | $20,55720 claims |
| Lilly USA, LLCMounjaro | $281 | $10,08211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in San Angelo
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.